171 related articles for article (PubMed ID: 22310977)
21. Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.
Li Y; Wang M; Zhu X; Cao X; Wu Y; Fang F
Dis Markers; 2019; 2019():2312439. PubMed ID: 31534561
[TBL] [Abstract][Full Text] [Related]
22. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
23. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Pallai R; Bhaskar A; Sodi V; Rice LM
Transcription; 2012; 3(6):323-35. PubMed ID: 23117818
[TBL] [Abstract][Full Text] [Related]
24. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
25. The role of CIP2A in cancer: A review and update.
Soofiyani SR; Hejazi MS; Baradaran B
Biomed Pharmacother; 2017 Dec; 96():626-633. PubMed ID: 29035828
[TBL] [Abstract][Full Text] [Related]
26. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
Zhai M; Cong L; Han Y; Tu G
Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
[TBL] [Abstract][Full Text] [Related]
27. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
28. [Expression and clinical significance of CIP2A in small cell lung cancer patients].
Deng Y; Xie K; Hu H; Yang L; Bai Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):517-20. PubMed ID: 26463328
[TBL] [Abstract][Full Text] [Related]
29. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
[TBL] [Abstract][Full Text] [Related]
30. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract][Full Text] [Related]
31. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Birkman EM; Elzagheid A; Jokilehto T; Avoranta T; Korkeila E; Kulmala J; Syrjänen K; Westermarck J; Sundström J
Cancer Med; 2018 Mar; 7(3):698-706. PubMed ID: 29441695
[TBL] [Abstract][Full Text] [Related]
32. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.
Xu P; Xu XL; Huang Q; Zhang ZH; Zhang YB
Med Oncol; 2012 Sep; 29(3):1643-7. PubMed ID: 21874565
[TBL] [Abstract][Full Text] [Related]
33. CIP2A is overexpressed in esophageal squamous cell carcinoma.
Qu W; Li W; Wei L; Xing L; Wang X; Yu J
Med Oncol; 2012 Mar; 29(1):113-8. PubMed ID: 21140243
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance.
Wang X; Yang R; Wang Q; Wang Y; Ci H; Wu S
Medicine (Baltimore); 2019 Sep; 98(36):e17028. PubMed ID: 31490389
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma.
Shi F; Ding Y; Ju S; Wu X; Cao S
Biomarkers; 2014 Feb; 19(1):70-6. PubMed ID: 24369732
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.
Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M
Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288
[TBL] [Abstract][Full Text] [Related]
37. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Ma N; Zhang L; Bian JM; Cao HY
Tumour Biol; 2013 Aug; 34(4):2309-13. PubMed ID: 23568706
[TBL] [Abstract][Full Text] [Related]
38. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
39. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival.
Ren J; Li W; Yan L; Jiao W; Tian S; Li D; Tang Y; Gu G; Liu H; Xu Z
Br J Cancer; 2011 Dec; 105(12):1905-11. PubMed ID: 22075943
[TBL] [Abstract][Full Text] [Related]
40. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.
Wu J; Ding M; Mao N; Wu Y; Wang C; Yuan J; Miao X; Li J; Shi Z
J Pharmacol Sci; 2017 May; 134(1):22-28. PubMed ID: 28522217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
